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Mediastinal malignant germ cell tumours: 
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Renata Zaucha1, Hanna Karnicka-M∏odkowska2, Marzena We∏nicka-JaÊkiewicz1, 
Jacek Jassem1
Primary mediastinal malignant germ cell tumours (PMMGCT) account for 10-15% of anterior mediastinal masses. Given
their uncommon occurrence, methods of primary treatment are still to be defined. We present our experience with the
PMMGCT patients.
M a t e r i a l s  a n d  m e t h o d s.  A retrospective analysis was performed on 15 patients (5 women and 10 men, age: 16-46 years,
median age 33 yrs) treated at our institution between 1982 and 2000. This series included four cases of pure seminomas (female
counterpart – dysgerminomas), five seminomas along with other components, and six non-seminomas. Thirteen patients
underwent surgical procedures, including complete or incomplete resections or excisional biopsy only. All 15 patients received
combined treatment consisting of platinum-based chemotherapy, followed by radiotherapy and/or surgical removal of the
persistent mass.
R e s u l t s.  Median follow-up time of 6 months (range:1 mo.-17 yrs). Two of 4 patients with seminomas and 2 of 11 patients
with nonseminomas are alive and disease-free. Median survival for patients with pure seminomas/dysgerminomas vs. other
types was 10 and 47 months, respectively, actuarial 5-year survival 50% vs. 18%, respectively. One patient was lost to follow-
up. Two long-term survivors with nonseminomas had complete surgical excision of the mediastinal tumour mass. One
patient died due to treatment-related complications (postoperative acute respiratory distress syndrome – ARDS).
C o n c l u s i o n.  Despite progress in multidisciplinary management of PMMGCT, treatment results remain unsatisfactory.
Pierwotne z∏oÊliwe guzy zarodkowe Êródpiersia: opis 15 przypadków i przeglàd piÊmiennictwa
Pierwotne z∏oÊliwe nowotwory zarodkowe Êródpiersia (PZNZÂ) stanowià 10 do 15% guzów w tej lokalizacji. Ze wzgl´du na
ich rzadkie wyst´powanie nie opracowano jak dotàd standardowej metody leczenia.
M a t e r i a ∏ y  i m e t o d y.  Przeprowadzono retrospektywnà analiz´ wyników leczenia 15 chorych na PZNZÂ (5 kobiet i 10
m´˝czyzn w wieku od 16 do 46 lat, mediana 33 lata) hospitalizowanych w naszym oÊrodku w latach 1982-2000. W grupie tej
by∏y cztery przypadki czystych nasieniaków (u kobiet – rozrodczaków), pi´ç przypadków guzów mieszanych – nasieniaków
z udzia∏em innych guzów zarodkowych i szeÊç przypadków nowotworów zarodkowych bez utkania nasieniaka. Zabiegi chi-
rurgiczne pod postacià ca∏kowitego bàdê nieca∏kowitego wyci´cia guza, lub tylko pobrania materia∏u do badania histopato-
logicznego zastosowano u 13 chorych. Wszyscy chorzy otrzymali leczenie skojarzone z udzia∏em chemioterapii zawierajàcej po-
chodne platyny z nast´powà radioterapià i/lub operacyjnym usuni´ciem resztkowej masy guza.
W y n i k i.  Po szeÊciomiesi´cznej medianie obserwacji (zakres od 1 miesiàca do 17 lat) 2 z 4 chorych z nasieniakami i 2 z 11
chorych z nowotworami nienasieniakowymi ˝yje bez objawów nowotworu. Mediana czasu prze˝ycia wynosi∏a, odpowiednio,
10 i 47 miesi´cy, a prawdopodobieƒstwo 5-letniego prze˝ycia 50% i 18%, odpowiednio, u chorych z czystymi nasieniakami/
rozrodczakami i z pozosta∏ymi nowotworami. Jeden chory zginà∏ z obserwacji. Dwaj ˝yjàcy chorzy z guzami nienasieniakowy-
mi przebyli doszcz´tne chirurgiczne usuni´cie guza Êródpiersia. Jeden chory zmar∏ z powodu powik∏aƒ leczenia (pooperacyj-
ny ostry zespó∏ niewydolnoÊci oddechowej).
W n i o s k i.  Przeprowadzona analiza retrospektywna wykaza∏a, ˝e pomimo post´pu w wielodyscyplinarnym post´powaniu
w PZNZÂ, wyniki leczenia sà niezadowalajàce.
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Introduction
Primary mediastinal malignant germ cell tumours
(PMMGCT) comprise approximately 10 to 15% of all
adult anterior mediastinal tumours and about 2 to 5%
of all adult germ cell tumours [1, 2]. PMMGCT occur
more frequently in men than in women. The relative risk
of these tumours is increased several hundred-fold
in subjects with Klinefelter syndrome and 47, XXY
karyotype, but is much lower in mosaic Klinefelter
syndrome [3-5]. PMMGCT are known to be associated
with 250-fold increased relative risk of haematological
malignancies – particularly acute megakaryoblastic
leukaemia and myelodysplasia with abnormal mega-
karyocytes [6, 7]. The relative risk of a second non-
germinal and nonhaematological malignancy is compara-
ble to that in patients with primary testicular carcinoma,
whereas the risk of developing metachronous testicular
cancer is higher [8, 9].
The origin of PMMGCT remains unclear. Recent
studies have shown that extragonadal and gonadal germ
cell tumours have virtually the same cytogenetic pattern of
aberrations. The most common abnormalities include
triploid chromosomes, increased number of 12p, i(12p)
and tandem duplications within 12p [10,11]. The meiotic
midprophase spermatocyte seems to be the precursor of
all germ cell malignancies, irrespective of their location.
Mediastinal tumours arise from mismigrated transformed
primordial germ cells located along the urogenital ridge
between the sixth cervical and the second sacral vertebra,
whereas gonadal germ cell tumours in men arise in
premeiotic spermatocytes [12]. The differences within
histological subsets may be explained by cellular environ-
ment resulting in phenotype differences.
Before the introduction of platinum-based chemo-
therapy the prognosis in PMMGCT was extremely poor,
with only 3% of patients surviving longer than 16 months
[13]. The use of modern cisplatin-based chemotherapy
regimens has markedly improved therapeutic outcomes
[14-18]. Currently, radiotherapy is reserved for the
treatment of pure seminomas/dysgerminomas but as
a single modality it provides only approx. 60% of long-
term survival [19]. Mediastinal location of PMMGCT is
an independent poor prognostic factor regardless of
the level of tumour markers or metastatic status [20].
We present our experience with the management of
PMMGCT.
Patients and methods
Between the years 1982 and 2000 15 patients with PMMGCT
were referred to the Department of Oncology and Radiotherapy,
Medical University of Gdaƒsk, and to the Dept. of Chemo-
therapy PCK Hspital in Gdynia, Poland. This group consisted of
5 women and 10 men, aged 16-46 years (median 33 years).
Symptoms at presentation included chest pain, dyspnoea and
non-productive cough in 11 patients, symptoms of superior vena
cava syndrome in 7, hemoptysis and weakness in 2 cases each,
shoulder pain and weight loss in 1 case each. Gynecomastia was
present in one patient with cytogenetically confirmed Klinefelter
syndrome, whereas the gonads were normal in all patients on
clinical and ultrasound examinations. One patient had clinically
apparent metastases to the left supraclavicular lymph nodes.
Chest radiography revealed anterior mediastinal mass in all
cases, in 3 combined with hydrothorax (in two diagnosed as
hemothorax), in 3 – with malignant infiltration of the adjacent
pulmonary parenchyma, in 1 – with hilar involvement and in 1 –
with pulmonary metastases. Histopathology includeded pure
seminoma (female counterpart – dysgerminoma) in 4 cases, 5
cases of seminoma along with immature teratoma, embryonal
cell carcinoma, chorioncarcinoma, or teratocarcinoma and 6
pure nonseminomas. Histological diagnosis was established at
thoracotomy (4 patients), anterior mediastinotomy (3 patients),
sternotomy (6 patients) and CT-guided fine needle biopsy (2
patients). Baseline data included complete blood counts, routine
serum chemistries and tumour markers – HCG and AFP. Three
of patients with tumours containing elements of embryonal cell
carcinoma had elevated AFP levels, whereas HCG levels were
elevated in all 7 cases containing elements of chorioncarcinoma.
Patients treated in the early eighties didn't have markers
evaluated on a regular basis.
Tr e a t m e n t
Standard treatment of PMMGCT at our institution includes
surgical excision of the tumour, if feasible, followed by platinum-
based chemotherapy, with radiotherapy reserved for pure
seminomas, or for palliation of symptoms. Surgical procedures
were performed in 13 patients. Of those, complete resection of
the mediastinal mass and segmentectomy of the right lung was
performed in 1 case, and microscopically and macroscopically
incomplete resections – in 3 cases each. The remaining 6 cases
underwent excisional biopsy only. In 2 cases of seminoma
with components of chorioncarcinoma diagnosis was established
by CT-guided fine-needle aspiration biopsy. One of those
cases was initially misdiagnosed and treated as non small
cell lung cancer. Appropriate treatment was introduced
after a partial excision of the tumour had provided final
diagnosis.
All patients were offered 1 to 6 cycles of chemotherapy
including maximally 4 cycles of platinum-based regimens:
classical PVB regimen consisting of cisplatin, vinblastin and
bleomycin, BEP consisting of bleomycin, etoposide and cisplatin,
or BEP + methotrexate. One patient, who initially refused
chemotherapy was offered thoracic irradiation instead. Chemo-
therapy preceding surgery was administered in 2 patients. Of
those, 1 patient received 4 courses of cyclophosphamide,
dactinomycin and methotrexate followed by 2 courses of PVB,
and 1 received 4 courses of BEP combined with methotrexate.
Chemotherapy was given in full-prescribed doses. Seven patients
(4 with seminomas, 3 with non-seminomas) received thoracic
irradiation for residual tumours after completion of chemo-
therapy. Radiotherapy was delivered with 60Co photons, using
two parallel opposed fields. Total doses ranged from 30 to 45 Gy
given in 10 to 25 daily fractions. One patient was given radio-
therapy (total dose 20 Gy in 10 fractions) at the time of
progression for palliation of symptoms. Surgical removal of
residual masses was attempted in 2 cases.
Results
All 15 patients were evaluated for response to treatment
and survival (Table I). Median follow up was 6 months
(range 1 month to 17 years). Three of 4 patients with
pure seminomas partially responded to chemotherapy.
Of those, 2 received radiotherapy for the residual mass
and are alive and free of disease for 7 and 11 years
respectively, and 1 patient relapsed and died after 26
months. The fourth patient completely responded to
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Table I. Data on treatment and outcome of all patients
Patient Age/ Type of tumour Chemotherapy Radiotherapy Overall survival Treatment 
initials Sex (No. of cycles) /Total dose (Gy) (months) outcome
EB 23/F Dysgerminoma PVB 35 10 Died due to progression
(3)
LN 43/F Dysgerminoma PVB 30 132+ Alive, free of disease
(3)
JG 18/M Seminoma PVB 40 26 Died due to progression
(3)
MS 31/F Dysgerminoma BEP 40 84+ Alive and free of disease
(4)
BK 16/M Non seminoma MAC (5), 45 228+ Alive and free of disease
PVB (4)
KG 29/M Non seminoma PVB 20 10 Died due to progression
(4)
GZ 33/M Non seminoma BEP No 12 Lost to follow-up
(4)
TH 45/M Non seminoma BEP + M 45 10 Died with no evidence of tumor
(4)
AL 18/M Non seminoma BAMVO No 4 Died due to progression
(1)
TS 40/F Non dysgerminoma COCA 40 9+ Alive and free of disease
(4)
WW 42/M Non seminoma BEP No 6 Died due to progression
(2)
JN 35/M Non seminoma BEP No 2 Died due to progression
(1)
GK 38/F Non dysgerminoma BEP No 2 Died due to progression
(1)
AR 40/M Non seminoma BEP No 6 Died due to progression
(1)
JR 20/M Non seminoma BEP No 96+ Alive and free of disease
(4)
Legend: PVB: cisplatin, bleomycin, vinblastine; BEP: cisplatin, etoposide, bleomycin; MAC: methotrexate, adriamycin cyclophosphamide; BAMVO:
bleomycin, adriamycin, methotrexate, vinblastine, vincristine; COCA: cisplatin, vincristine, cyclophosphamide, adriamycin
+: patient alive
Figure 1. Kaplan-Meier analysis of survival for the entire group of patients
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thoracic irradiation alone, but shortly afterwards devel-
oped multiple cerebral metastases and died after 10
months.
Of the 11 patients with nonseminomas only 2 are
alive and free of disease. Of those, 1 patient underwent
complete surgical removal of the tumour mass with
normalization of the tumour markers, and then received
four courses of BEP chemotherapy. He has remained in
complete remission for 9 years. Another patient received
6 courses of chemotherapy followed by thoracic radio-
therapy. With normal levels of biochemical serum
markers, he was referred for surgical removal of the
residual mass 12 months after the completion of irra-
diation. Histopathological examination of the resected
specimen did not reveal viable tumour cells. He has been
alive and free of disease for 19 years. One patient who
showed clinical, radiological and biochemical partial
responded after to 4 courses of BEP+M received
subsequent radiotherapy and underwent removal of the
persistent mediastinal mass. He died due to postoperative
complications (ARDS) 10 months after the diagnosis
without evidence of malignancy in the resected surgical
specimen. One patient in complete response after
incomplete surgery and chemotherapy was lost to follow
up. The remaining 7 patients treated with chemotherapy
followed by thoracic irradiation developed both local and
distant progression and died within 2 to 10 months
(median: 5 mos) from the diagnosis. Median time of
survival for the entire group of patients was 10 months
(Figure 1); 47 and 10 months for seminomas and other
pathological types, respectively, whereas actuarial 5-year
survival 50% and 18%, respectively.
Discussion
Due to their rarity, therapy of PMMGCT has not been
assessed in prospective randomised trials. Patients with
PMMGCT are routinely treated with chemotherapy
regimens identical to those used in their gonadal counter-
parts. Bokemeyer et al. [18] have recently published data
on 635 PMMGCT patients, 54% of those with primary
mediastinal localization, treated at 11 American and
European institutions between 1975 and 1996. Their
results support the relative efficacy of cisplatin-based
chemotherapy followed by complete surgical removal of
residual mass. However, the optimal treatment strategies
for PMMGCT remain to be defined. Lower treatment
efficacy in patients with PMMGCT, as compared to
primary gonadal germ cell tumours, has not been
explained. It may result from a more advanced stage of
the disease at presentation. Unsatisfactory results of
treatment presented in this case series support previously
published data which has shown that effective chemo-
therapy and completeness of surgical excision are
essential in the management of PMMGCT. Interestingly,
none of our patients completely responded to chemo-
therapy. Similar results were reported [21,22], although
there are numerous examples of complete remissions
even in patients with massive PMMGCT [2, 22-24]. Bower
et al [25] reported excellent results in 16 patients treated
with POMB/ACE regimen – 15 complete responses and
a 73% 5-year survival. Currently, the role of post-
chemotherapy aggressive surgery for residual mass is
unquestionable [18, 26]. It should be emphasized that
the presence or absence of viable tumor cells is the most
important predictor of survival [27] If malignant cells are
still present in the resected specimen, additional chemo-
therapy is usually recommended [24, 25]. Indeed, 2 long-
term survivors in our group were treated with timed
aggressive surgery following systemic treatment. In
contrary, 2 patients ineligible for surgery had the shortest
survival. The role of radiotherapy in PMMGCT is less
defined. In this series radiotherapy proved ineffective.
Generally, this modality is considered useful in pure
seminomas/dysgerminomas, but less so in other germ-
cell tumours. Hurt et al [28] have reported high local
control rate after thoracic radiotherapy with the doses
of 30 to 35 Gy followed by a boost dose of 5 Gy for
primary mediastinal seminoma. However, 8 patients in
this series have died because of distant metastases, and
long-term survival was only 52% [28]. Bush et al [29],
using doses in the range of 35 to 60 Gy achieved a 69%
ten-year survival with a 54% relapse-free survival. Six of
13 patients in that series relapsed within the irradiated
volume. Kersh et al [30] reported 100% five-year survivals
in a group of 12 patients with primary mediastinal
seminomas after radiotherapy doses ranging from 30 to 50
Gy. In contrast, no local control was achieved in 9 patients
with nonseminomas and the overall survival was only
8.8%. These results may either question the role of
radiotherapy in PMGCT or emphasize the role of
precisely performed pathological examination. Some of
the „pure seminomas” may in fact contain other histo-
logical components. In our series, one patient with
mediastinal seminoma achieved complete response after
the total dose of 40 Gy, but subsequently he developed
cerebral metastases and died within 4 months from
diagnosis. One patient with mixed nonseminoma with
incomplete response to chemotherapy was administered
radiotherapy (45 Gy). Persistent residual mediastinal
tumour was later resected, but no viable malignant cells
were found in the specimen. However, the patient died
due to postoperative complications (ARDS). Another
patient managed by chemotherapy followed by
radiotherapy and surgical removal of the necrotic mass
has been alive and free of the disease for 14 years. This
may arise from the addition of radiotherapy to aggressive
chemotherapy, although it may well reflect our inability to
distinguish small deposits of viable tumour cells from the
necrotic tissue. Indeed, in all partial responders to
chemotherapy, further radiation up to the total dose of 35
Gy was ineffective. These patients died due to local and
distant progression. One may discuss whether the total
dose was suboptimal or tumour burden was too big.
Our results support the view that prognosis in
PMMGCT differs among histological subtypes, and is
better for pure seminomas than for other germ-cell types
(50% vs. 18% actuarial 5-year survival). In the former
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group the extent of the disease, response to systemic
treatment, and histological tumour type in the residual
specimen seem to have prognostic value [21,26]. As in
gonadal tumours, serum tumour markers are useful in
treatment monitoring. Normalising levels during chemo-
therapy correlate with remission, whereas elevated levels
strongly suggest persistent disease. Unfortunately the lack
of regular measurements of serum tumour markers in
our patients has rendered such analysis impossible.
In conclusion, PMMGCT are rare tumours with
unfavourable prognosis. Cases with pure seminomatous
histology with no bulky disease may be effectively treated
with definitive radiotherapy. All other histological
subtypes and bulky seminomas should be managed with
cisplatin-based chemotherapy followed by radical
resection of residual mass. In case of persistent
malignancy in the resected specimen further chemo-
therapy is mandatory.
Renata Zaucha MD, PhD
Department of Oncology and Radiotherapy
Medical University of Gdaƒsk
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